An independent peptide reference — no sellers, every claim sourced

Oxytocin

Also known as Syntocinon, Pitocin

Registered obstetric hormone; the popular intranasal use for social behaviour is largely experimental.

clinically proven Hormonal & sexual approved drug

At a glance

Category
Hormonal & sexual
Status
approved drug
Made from
synthetic Chemically synthesised. The label states this explicitly, because the older approach of extracting it from mammalian posterior pituitary carried contamination with vasopressin and other pituitary peptides.
Route
intravenous or intramuscular (registered); intranasal (research)
Half-life
plasma half-life of about 1 to 6 minutes, decreased in late pregnancy and during lactation 6
Onset
Intravenously within minutes; intranasally, behavioural effects in studies usually appear after 30-45 minutes
Molecular weight
1007.2 g/mol
Sequence
Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 (cyclic via the Cys1-Cys6 disulfide bridge)

As a solution for infusion and injection, oxytocin is registered worldwide for obstetric indications: inducing or augmenting labour and controlling postpartum bleeding 6. The US label states explicitly that oxytocin is not indicated for elective induction of labour 6. It is on the WHO list of essential medicines. Intranasal administration for social, cognitive or psychiatric purposes is not registered; the former Syntocinon nasal spray for initiating the let-down reflex has been withdrawn from the market in most countries.

Doping status: Not listed by WADA

Checked against the WADA 2026 Prohibited List. For a specific product and country, Global DRO is the lookup athletes are expected to use — the List names substances, not brand names.

Mechanism of action

Oxytocin is a nine-amino-acid peptide hormone that is produced in the hypothalamus and released via the posterior pituitary. It acts on the oxytocin receptor, a G protein-coupled receptor that raises the intracellular calcium concentration via the Gq pathway.

Peripherally the effect is well understood: contraction of the smooth muscle of the uterus and of the myoepithelial cells around the milk ducts. The sensitivity of the uterus to oxytocin increases sharply during pregnancy because the number of receptors rises.

Centrally, oxytocin is also released as a neuromodulator in the amygdala, nucleus accumbens and prefrontal cortex among other regions, where it influences social salience and anxiety regulation. How intranasal administration achieves this is, however, an unresolved problem: it has not been convincingly demonstrated how much oxytocin actually reaches the brain via the olfactory or trigeminal nerve, and effects in behavioural studies may partly be indirect, via peripheral receptors or via vagal feedback. In addition, oxytocin shows cross-reactivity with the vasopressin V1a receptor, which complicates interpretation further.

What the research shows

A sharp distinction must be made between two applications. For the obstetric indications, oxytocin is one of the best-supported medicines there are. For intranasal use to influence trust, empathy or autism symptoms the picture is very different: many early positive findings have not been replicated, meta-analyses find small to negligible effects 2, and the largest and best-designed studies come out predominantly negative.

Research in humans

Obstetric: decades of randomised research and clinical experience; oxytocin is the standard for induction of labour and for active management of the third stage. Intranasal: the influential early study on increased trust (2005) has not been confirmed in later, larger replication attempts 4. A registered report with equivalence testing found no meaningful effect of intranasal oxytocin on trusting behaviour 4. A meta-analysis of social cognition in neurodevelopmental disorders found no significant effect on emotion recognition (Hedges' g approximately 0.08) and only a small effect on theory of mind (g approximately 0.21) 2. The largest randomised study in children with autism (SOARS-B, published in the New England Journal of Medicine in 2021) found no difference from placebo on social outcome measures. Not everything points one way: an earlier meta-analysis by Van IJzendoorn and Bakermans-Kranenburg reported that intranasal oxytocin does enhance recognition of facial emotional expressions and raises trust towards an in-group, while the expected decrease in trust towards an out-group was not confirmed 3. It is the sort of positive pooled result, drawn from small early studies, that the later and larger replication attempts did not bear out — which is the pattern of this literature rather than an exception to it.

Animal and lab research

In prairie voles and rodents the role of oxytocin in pair bonding, maternal care and social recognition is well established. These findings have driven the human research, but translation to humans is problematic: the species differ greatly in receptor distribution and in social organisation.

Caveats. The intranasal research field suffers from small samples, publication bias in favour of positive results, widely varying doses and measurement times, and the unresolved problem of whether the substance reaches the brain at a relevant concentration at all. Effects also turn out to be strongly context-dependent: in some studies oxytocin actually increases aversion to outsiders and jealousy. The frequently heard description as the 'cuddle hormone' is not supported by the current data.

What it is used for

  • Inducing or augmenting labour where medically indicated (registered, in hospital) 6
  • Controlling postpartum bleeding and producing contractions in the third stage of labour (registered) 6
  • Management of incomplete or inevitable abortion (registered) 6
  • Research into social cognition, trust, anxiety and autism spectrum disorder — experimental, with predominantly disappointing results
  • Research into use in schizophrenia, social anxiety and addiction — no confirmed efficacy

Dosing

Dose
Three separate figures on three different scales, set out one by one in the notes below. They are not interchangeable: the obstetric infusion is measured in milli-IU per minute, which is a thousandth of an IU, while the intramuscular and intranasal figures are whole IU.
Frequency
Obstetric according to hospital protocol with titration against the contraction pattern. In research: a single dose, or twice daily for weeks
Route
intravenous or intramuscular (registered); intranasal (research only)
Duration
Obstetric hours; research protocols ran from a single dose to 24 weeks
  • Induction or augmentation of labour, intravenous infusion by pump, hospital only: titrated in milli-IU per minute against the contraction pattern. Hospital protocols commonly span roughly 1 to 32 milli-IU per minute, but the Pitocin label notes that rates up to 6 milli-IU per minute give the oxytocin levels found in spontaneous labour and that rates above 9-10 milli-IU per minute are rarely required at term 6. Sustained rates of 40-50 milli-IU per minute infused for long periods are the range associated with water intoxication 6.
  • Control of postpartum uterine bleeding, intramuscular, single dose: 10 IU after delivery of the placenta on the US label 6; 5 IU is used in some other markets. This is a whole-IU dose given once, and it has nothing to do with the milli-IU-per-minute infusion figure above.
  • Behavioural research, intranasal, per occasion: usually 24 IU. This is a research route with no registered indication, and the intranasal figure cannot be compared with either injected figure — nasal bioavailability is a small and poorly characterised fraction.
  • Obstetric use should take place exclusively in hospital, with continuous monitoring of contraction activity and fetal heart tones. Overdosing causes hyperstimulation of the uterus with a risk of rupture and fetal distress.
  • The 24 IU that is customary in behavioural research is largely historically determined and not derived from dose-finding research. A systematic review of 75 studies established that most used that single dose without justification.
  • There is no established dosing schedule for non-obstetric use, because there is no registered indication.
  • With prolonged infusion involving large volumes of fluid, water intoxication with hyponatraemia is a real risk, because oxytocin has an antidiuretic effect.

These figures describe what the literature and published protocols report. They are not advice and not a dosing instruction.

Reconstitution

Vial sizes
5 IU/ml ampoule, 10 IU/ml ampoule
Solvent
Not applicable: the registered product is a ready-to-use solution that is diluted for infusion in 0.9% sodium chloride or another infusion fluid named by the manufacturer
Storage
Store ampoules at 2-8 °C, protected from light; do not freeze. Some preparations may be kept at room temperature for a limited time — follow the package leaflet.

Worked example

A common hospital protocol dilutes 10 IU oxytocin in 500 ml 0.9% sodium chloride (20 milli-IU/ml) for controlled infusion via a pump.

Oxytocin is not reconstituted from powder like many research peptides. Compounding your own nasal spray from injection solution has not been studied for stability, sterility or delivered dose.

Safety

Side effects

  • Obstetric: hyperstimulation of the uterus, with a risk of uterine rupture and fetal distress 6
  • Nausea and vomiting 6
  • Headache
  • Cardiac arrhythmia, premature ventricular contractions and fetal bradycardia 6; a fall in blood pressure with rapid intravenous administration
  • Water intoxication with hyponatraemia, confusion, convulsions and coma with prolonged infusion involving a lot of free water; maternal death from oxytocin-induced water intoxication has been reported 6
  • Hypersensitivity reactions, including anaphylaxis (rare) 6
  • Intranasal in research: usually mild — headache, nasal irritation, drowsiness. In some studies, conversely, intensified negative social reactions such as jealousy or aversion to out-groups

Do not use if

  • Any situation in which vaginal delivery is contraindicated: transverse lie, cord prolapse, placenta praevia, vasa praevia, cervical carcinoma, genital herpes, or significant cephalopelvic disproportion 6
  • Fetal distress when delivery is not imminent 6
  • Hypertonic or hyperactive contraction activity 6
  • Hypersensitivity to oxytocin 6
  • Severe cardiovascular disease
  • Non-obstetric, intranasal use outside a study setting: safety with repeated use over longer periods has not been established, and home-made nasal sprays from injection solution or from grey-market powder have no controlled dose

Interactions

Prostaglandins enhance the uterotonic effect; concurrent use increases the risk of hyperstimulation and requires monitoring. Some inhalational anaesthetics (such as sevoflurane) reduce uterine contraction and can weaken the effect. Vasoconstrictors and sympathomimetics can cause severe hypertension in combination with oxytocin, particularly after epidural anaesthesia 6; cyclopropane anaesthesia has been associated with hypotension and arrhythmias 6. Oxytocin enhances the antidiuretic effect of other agents that cause fluid retention.

Sources